Ocrevus off to a running start in US multiple sclerosis market

20 July 2017

A survey of 104 American neurologists in June showed almost half had already prescribed Ocrevus (ocrelizumab), Genentech’s newly-approved treatment for relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

The report, from market intelligence firm Spherix Global Insights, indicates a high level of anticipation for the drug, which is the first disease-modifying therapy (DMT) approved to treat PPMS.

Nearly 80% of those surveyed expect to be using the drug within the next six months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK